Treatment of Menorrhagia

Menorrhagia is the loss of excessive amounts of blood at the time of menstruation. Definitions are far from precise, and there is little agreement on exact usage among clinicians from different centres. Here the term is used to mean a complaint of excessively heavy bleeding irrespective of its regularity or frequency. Objective confirmation of excessive bleeding in clinical practice is difficult, and numerous studies have demonstrated that there is little correlation between a complaint of heavy bleeding and research measurements of a loss of greater than 80 ml per menstrual period [1–4]. This chapter will attempt to take into account the difference between the broadly accepted clinical diagnosis and the narrower objective research definition. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

Hallberg L, Hogdahl A-M, Nilsson L, Rybo G. Menstrual blood loss-a population study. Acta Obstet Gynecol Scand 1966; 45:320–51. Chimbira T, Anderson ABM, Turnbull AC. Relation between measured menstrual blood loss and patients’ subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstet Gynaecol 1980; 87:603–9. Fraser IS, Pearse C, Shearman RP, Elliott PM, Mcllveen J, Markham R. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynecol 1981; 58:543–51. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984; 149: 788–93. Fraser IS. Treatment of menorrhagia. In: Drife JO, ed. Dysfunctional uterine bleeding and menorrhagia. Bailliere’s Clinical Obstetrics and Gynaecology 1989; 3:391–402. Fraser IS, McCarron G, Markham R. Blood and total fluid content of menstrual discharge. Obstet Gynecol 1985; 65:194–8. Rock JA, Hurst BS. Clinical significance of prostanoid concentration in women with endometrio-sis. In: Chadha DR, Buttram VC, eds. Current concepts in endometriosis. Progress in clinical and biological research, Vol. 323. New York: Alan R Liss, 1990; 61–80. Smith SK. The endometrium and endometriosis. In: Thomas EJ, Rock JA, eds. Modern approaches to endometriosis. Dordrecht: Kluwer Academic Publishers, 1991; 57–77. Fraser IS. Hysteroscopy and laparoscopy in women with menorrhagia. Am J Obstet Gynecol 1990; 162:1264–9. Fraser IS, McCarron G, Markham R. Objective measurement of menstrual blood loss in women with a complaint of menorrhagia associated with pelvic disease or coagulation disorder. Obstet Gynecol 1986; 68:630–3. Kauppila A, Puolakka J, Ylikorkala O. Prostaglandin biosynthesis inhibitors and endometriosis. Prostaglandins 1979; 18:655–61. Baird DT, Abel MH, Kelly RW, Smith SK. Endocrinology of dysfunctional uterine bleeding: the role of endometrial prostaglandins. In: Crosignani PG, Rubin BL, eds. Endocrinology of human infertility; new aspects. New York: Academic Press, 1981; 399–417. Pizarro E, Schoenstedt G, Mehech G, Hidalgo M, Romero C, Munoz G. Uterine cavity and the location of IUDs following administration of meclofenamic acid to menorrhagic women. Contraception 1989; 40:413–23. Brooks PG, Serden SP. Hysteroscopic findings after unsuccessful dilatation and curettage for abnormal bleeding. Am J Obstet Gynecol 1888; 158:1354–7. Loffer FD. Hysteroscopy with selective endometrial sampling compared with dilatation and curettage for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstet Gynecol 1989; 73:16–20. Whitehouse HB. The physiology and pathology of uterine haemorrhage. Lancet 1914; i:951–7. Boctor A, Eickholt M, Pugsley IA. Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclo-oxygenase pathways of the arachidonic cascade in vitro. Prostaglandin Leukotrienes Med 1986; 23:229–38. Flowers RJ, Vane JR. Inhibition of prostaglandin synthesis. Biochem Pharmacol 1974; 23:1439–50. Rees MCP, Canete-Soler R, Bernai AL, Turnbull AC. Effect of fenamates on prostaglandin E receptor binding. Lancet 1988; 1:541–2. Anderson ABM, Haynes PJ, Guillebaud J, Tumbull AC. Reduction of menstrual blood loss by prostaglandin synthetase inhibitors. Lancet 1976; i:774–6. Jacubowicz DL, Wood C. The use of the prostaglandin synthetase inhibitor mefenamic acid in the treatment of menorrhagia. Aust NZ J Obstet Gynaecol 1979; 18:135–42. Haynes PJ, Flint AP, Hodgson H, Anderson ABM, Turnbull AC. Studies in menorrhagia: a) mefenamic acid; b) endometrial prostaglandin concentration. Int J Gynaecol Obstet 1980; 17:567–72. Wood C, Jacubowicz DL. The use of mefenamic acid in the treatment of menorrhagia and other menstrual symptoms in specialist practice. Res Clin Forums 1982; 14:111–22. Fraser IS, McCarron G, Markham R. Long-term treatment of menorrhagia with mefenamic acid. Obstet Gynecol 1983; 61:109–12. Muggeridge J, Elder MG. Mefenamic acid in the treatment of menorrhagia. Res Clin Forums 1983; 5:83–8. Hall P, Maclachlan N, Thorn N, Hudd MWE, Taylor CG, Garrioch DB. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol 1987; 94:554–8. Dockeray CJ. The use of prostaglandin synthetase inhibitors in dysfunctional uterine bleeding. In: Shaw RW, ed. Dysfunctional uterine bleeding. Carnforth: Parthenon Press, 1990; 117–25. Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 1990; 76:85–8. Grover V, Usha R, Gupta U, Kaira S. Management of cyclical menorrhagia with a prostaglandin synthetase inhibitor. Asia Oceania J Obstet Gynaecol 1990; 16:255–9. Fraser IS, McCarron G. Randomised trial of two hormonal and two prostaglandin inhibiting agents for the treatment of menorrhagia. Aust NZ J Obstet Gynaecol 1991; 31:66–70. Rybo G, Nilsson S, Sikstrom B, Nygren KG. Naproxen in menorrhagia. Lancet 1981; i:608–9. Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986; 68:10–16. Vargyas JM, Campeau JD, Mishell DR, jr. Treatment of menorrhagia with meclofenamate sodium. Am J Obstet Gynecol 1987; 157:944–50. Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglan-dins and effect of ibuprofen. Br J Obstet Gynaecol 1986; 93:974–83. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol 1983; 90: 78–87. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164:879–93. Fraser IS. The treatment of menorrhagia with mefenamic acid. Res Clin Forums 1983; 5:93–9. Meyboom RH, Bonsema K, Huisman-Klein Haneveld PM. Can naproxen impair menstruation? Ned Tijdschr Geneeskd 1989; 133:1326–7. Mira M, Fraser IS, McNeil D, Vizzard J, Abraham S. The use of mefenamic acid in treatment of premenopausal tension sufferers. Obstet Gynecol 1986; 68:395–8. Guillebaud J, Anderson ABM, Turnbull AC. Reduction by mefenamic acid of increased menstrual blood loss associated with intrauterine contraception. Br J Obstet Gynaecol 1978; 85:53–60. Ylikorkala O, Kauppila A, Siljander M. Antiprostaglandin therapy in prevention of side-effects of intrauterine contraceptive devices. Lancet1978; ii:393–5. Davies AJ. Reduction of menstrual blood loss by naprooxen in intrauterine contraceptive device users. Int J Gynaecol Obstet 1980; 17:353–4. Davies AJ, Anderson ABM, Turnbull AC. Reduction by naproxen of excessive menstrual bleeding in women using intrauterine devices. Obstet Gynecol 1981; 57:74–8. Roy S, Shaw ST. Role of prostaglandins in IUD-associated uerine bleeding — effect of a prostaglandin synthetase inhibitor (ibuprofen). Obstet Gynecol 1981; 58:101–6. Toppozada M, Anwar M, Abdel Rahman H, Gaweesh S. Control of IUD-induced bleeding by three non-steroidal anti-inflammatory drugs. Contracept Deliv Systems 1982; 3:117–25. Makarainen L, Ylikorkala O. Ibuprofen prevents IUCD-induced increases in menstrual blood loss. Br J Obstet Gynaecol 1986; 93:285–8. Bishop PMF, de Almeida JCC. Treatment of functional menstrual disorders with norethisterone. Br Med J 1960; 1:1103–6. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust NZ J Obstet Gynaecol 1990; 30:353–6. Bergqvist A, Rybo G. Treatment of menorrhagia with intrauterine release of progesterone. Br J Obstet Gynaecol 1983; 90:255–8. Andersson K, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97:690–4. Turnbull AC, Rees MCP. Gestrinone in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97:713–15. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971; 110:713–20. Chimbira T, Anderson ABM, Turnbull AC. Reduction of menstrual blood loss with danazol in unexplained menorrhagia; lack of effect of placebo. Br J Obstet Gynaecol 1980; 87:1152–7. Shaw RW, Fraser HM. Use of a superactive luteinizing hormone-releasing hormone agonist in the treatment of menorrhagia. Br J Obstet Gynaecol 1984; 91:913–19. McLachlan RI, Healy DL, Burger HG. Clinical aspects of LHRH analogues in gynaecology: a review. Br J Obstet Gynaecol 1986; 93:431–54. Petrucco OM, Fraser IS. The potential for use of GnRH agonists for the treatment of dysfunctional uterine bleeding. In: Developments in the treatment of benign gynecological disorders. Am J Obstet Gynecol, (Suppl) 1992 (in press). Nilsson L, Rybo G. Treatment of menorrhagia with an anti-fibrinolytic agent, tranexamic acid (AMCA): a double blind investigation. Acta Obstet Gynecol Scand 1967; 46:572–80. Harrison R, Campbell S. A double-blind trial of ethamsylate in the treatment of primary and intrauterine device menorrhagia. Lancet 1976; ii:283–5. Fraser IS. Menorrhagia due to myometrial hypertrophy and its successful treatment with the anti-estrogen, tamoxifen. Obstet Gynecol 1987; 27:244–7. Pavlin V, Flynn MJ, Mulder JL, Cort JH. The treatment of uterine bleeding with vasopressin homonogen (Glypressin) — a pilot study. Br J Obstet Gynaecol 1978; 85:801–5. Rumbolz WL, Moon CF, Norelli JC. Use of protamine sulphate and toluidine blue for abnormal uterine bleeding. Am J Obstet Gynecol 1952; 63:1029–36. Selwood T, Wood C. Incidence of hysterectomy in Australia. Med J Aust 1978; 2:201–4. McIntosh MCM. Incidence of hysterectomy in New Zealand. NZ Med J 1987; 100:345–7. Goldrath MH, Fuller TA, Segal S. Laser photo vaporization of endometrium for the treatment of menorrhagia. Am J Obstet Gynecol 1981; 140:14. Magos AL, Baumann R, Lockwood GM, Turnbull AC. Experience with the first 250 endometrial resections for menorrhagia. Lancet 1991; 337:1074–8. Townsend DE, Richart RM, Paskowitz RA, Woolfork RE. “Rollerball” coagulation of the endometrium. Obstet Gynecol 1990; 76:310–13. Phipps JH, Lewis BV, Roberts T, Prior MV, Hand JW, Elder M, Field SB. Treatment of functional menorrhagia by radiofrequency-induced thermal ablation. Lancet 1990; 335:374–6. Editor information Editors and Affiliations Rights and permissions Copyright information © 1992 Royal College of Obstetricians and Gynaecologists About this chapter Cite this chapter Fraser, I.S. (1992). Treatment of Menorrhagia. In: Drife, J.O., Calder, A.A. (eds) Prostaglandins and the Uterus. Springer, London. https://doi.org/10.1007/978-1-4471-1931-9_5 Download citation DOI: https://doi.org/10.1007/978-1-4471-1931-9_5 Publisher Name: Springer, London Print ISBN: 978-1-4471-1933-3 Online ISBN: 978-1-4471-1931-9 eBook Packages: Springer Book Archive

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.